New appointment at Catalyst Biosciences
This article was originally published in Scrip
Catalyst Biosciences, a US company focused on the discovery and development of engineered proteases known as Alterase therapeutics, has named William Dawson chief financial officer. He has more than 30 years' financial management and business development experience, having previously served as vice-president of finance and chief financial officer at Cerus.
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.